{"id":"W3012570191","doi":"10.1016/s2352-3026(20)30070-3","title":"Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Multiple myeloma; Internal medicine; Refractory (planetary science); Adverse effect; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Surgery; Clinical trial; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001931769,0.002104486,0.003064942,0.0004130012,0.0005968682,0.001910851,0.001125052,0.002032553,0.008603855],"category_scores_gemma":[0.001898355,0.0008247371,0.002916807,0.0005719058,0.001757881,0.001361763,0.00079,0.004388568,0.00176243],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001234643,"about_ca_system_score_gemma":0.001410441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002306323,"about_ca_topic_score_gemma":0.004672965,"domain_scores_codex":[0.9992449,0.0004069376,0.00002785232,0.0001314848,0.00004552601,0.000143311],"domain_scores_gemma":[0.9990714,0.0002697348,0.0002134246,0.00007410191,0.00004581245,0.0003254414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9842098,0.002834482,0.0003647095,0.0004881272,0.0009326368,0.0000372178,0.00006353201,0.0002026965,0.001634425,0.00009268738,0.0007097239,0.008429947],"study_design_scores_gemma":[0.9826224,0.01563467,0.0008021654,0.00002581516,0.0002451539,0.0000184939,0.00001962779,0.0001366053,0.0000814634,0.0000941614,0.0003107067,0.000008757723],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845813,0.006654491,0.0007059145,0.0015906,0.00115495,0.002047722,0.00102546,0.0001775379,0.002062117],"genre_scores_gemma":[0.9860366,0.002772657,0.001448271,0.001900165,0.0004326287,0.002511414,0.0009806451,0.0000411531,0.003876345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008603855,"threshold_uncertainty_score":0.02878273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08514856475611958,"score_gpt":0.3579203474354993,"score_spread":0.2727717826793797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}